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a b s t r a c t
Objectives: To explore patient perception of the role of a nurse-led complex package of care in facilitating
engagement with urate-lowering therapies (ULTs) in the management of gout.
Methods: Thirty people who had participated in a randomised controlled trial investigating the effect
of a nurse-led complex package of care for gout, were purposively sampled and interviewed between
18–26months after the end of the trial. Interviews were recorded, transcribed and analysed using a
modified grounded-theory approach. Data were managed using Nvivo. STATA v15 was used to describe
summary statistics.
Results: Participants described their views and experiences of engaging with a nurse-led intervention
designed to provide holistic assessment, individualised patient education, and involvement in shared
decision-making for the long-term management of gout. The analysis revealed key themes in how
nurse-led intervention facilitated engagement with ULT, namely by proving improved knowledge and
understanding of gout and its treatment, involvement of patients in decision-making about treatment,
and increased confidence about benefits from treatment. However, some treatment uncertainty and con-
cern remained and one participant free of gout flares discontinued ULT, while another halved the dose
after the end of the trial.
Conclusions: This study reports data on patient experience of engaging with ULT to manage gout after
receiving nurse-led care. It demonstrates that shared decision-making and the joint efforts of fully
informed practitioners and patients persuades patients to engage with ULTs, and that experiencing the
benefits of curative treatment motivates them to maintain adherence.
© 2018 Socie´te´ franc¸aise de rhumatologie. Published by Elsevier Masson SAS. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Gout is the most common inflammatory arthritis worldwide.
Between3.7–3.9% of adults in France and theUSA self-report physi-
cian diagnosed gout, while 2.5% of UK adults have gout according
to their primary care healthcare records [1–3]. The incidence and
prevalence of this condition are rising mainly due to an ageing
population, and the obesity epidemic [4]. Gout is also the only
rheumatic disease whose aetiopathogenesis is well understood,
and which can potentially be cured by removal of the pathogenic
agents (urate crystals) [5]. Current guidelines recommend the use
of urate-lowering therapies (ULTs) for people with recurrent flares
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or with complications such as tophi, renal stones, joint damage or
impaired renal function [6–8]. Up-titration of ULT to reduce and
maintain serum urate (SU) levels below 360mol/L is the key to
achieving long-term control of gout [6–8].
The uptake of ULTs is an important factor in its long-term
management. Despite the availability of effective pharmacologic
therapies, management of the condition remains suboptimal
[9,10]: only 30%–40% of patients with gout are ever prescribed
ULTs [1,11,12] and there is frequent absence of regular monitoring
and dose up-titration against a target SU level [13–16]. Treatment
adherence remains low: 70% of patients prescribed ULTs have gaps
in their use, mostly during the first year of treatment [17]. The
decision to initiate, persist on, and comply with a treatment is
influenced by a combination of physician and patient factors [18].
Evidence from a previous proof-of-concept study from Not-
tingham, UK, demonstrated that people with gout who are fully
informed about the disease and are involved in decisions about
https://doi.org/10.1016/j.jbspin.2018.10.008
1297-319X/© 2018 Socie´te´ franc¸aise de rhumatologie. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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their treatment wish to receive ULT and subsequently persist with
it [19]. Nurses manage many chronic conditions in the commu-
nity and provide personalised support and care [20]. Indeed, data
from the recent two-year randomised controlled trial (RCT) com-
paring nurse-led complex package of care for gout versus usual GP
care demonstrates that a nurse-led package of care combining indi-
vidualised patient education and engagement, lifestyle advice, and
ULT using a treat-to-target approach improves drug persistence,
reduces flare frequency and tophi, and improves quality of life [21].
The aim of this study was to qualitatively explore patients’ percep-
tions of the role of nurse-led care in this RCT in facilitating their
engagement with ULT.
2. Methods
2.1. Study design
Semi-structured qualitative interview study using elements of
grounded-theory methodology including open and axial coding,
constant comparison, and theoretical sampling [22]. Applying ele-
ments of grounded theory allows the study findings to be rooted in
participants’ experiences, highlighting what is important to them.
2.2. Ethical approval
Research ethics committee approvalwas obtained from theUni-
versity of Nottingham, Medical School Research Ethics committee
(referenceNo.: D16012017). All participants gavewritten informed
consent before data collection.
2.3. Sampling
Two hundred and fifty-five participants randomised to the
nurse-led care arm of the RCT were mailed a questionnaire about
gout and its current treatment after the end of the study. The first
100 participants who were contacted with the survey were also
approached to participate in an interview study. Of these, 52 peo-
ple showed an interest in participating in the interview study, and
30 people (58%) were sampled to reflect differences across gender,
age, ethnicity disease duration and type of ULT (i.e. allopurinol,
fexbuxostat or benzbromarone) and were purposively recruited.
The theoretical sampling approach requires researchers to begin
with an open-ended sampling strategy, use opportunistic inter-
views and then, through an iterative process of data collection and
analysis, refine the sampling strategy to be increasingly focused
until theoretical saturation is reached [22]. ZL and AA met reg-
ularly to discuss the process of refining the sampling strategy to
reach saturation.
2.4. Data collection
ZL designed a semi-structured interview guide in discussion
with AA and MD. The agreed-upon questions focused on patients’
perceptions of management of gout before, during and after the
nurse-led intervention and covered areas such as their beliefs
about the causes and consequences of gout, their symptoms (fre-
quency and severity), the impact of their condition on their daily
life and psychological and emotional wellbeing, medical manage-
ment of their condition, their perception of ULT, previous contact
with healthcare professionals and advice and information they had
received, their treatment history and preferences, and their level
of adherence to healthcare-professional advice about treatment.
ZL piloted the interview schedule with a few participants and no
revisions were required. WJ, a research nurse, contacted partic-
ipants by telephone to arrange an interview with ZL. Interviews
lasted twenty to ninety minutes. Twenty-two participants opted to
Table 1
Index of Multiple Deprivation (IMD) score for study participants.
Median (interquartile range)
Overall IMD 5 (2–7)
IMD domains
Income deprivation 4 (3–6)
Employment deprivation 4 (3–6)
Education, skills and training Deprivation 4 (2–6)
Health deprivation and disability 4.5 (2–6)
Crime 5 (3–7)
Barriers to housing and services 7 (5–9)
Living environment deprivation 5 (4–7)
be interviewed in the City Hospital Nottingham, in a private room
located in Academic Rheumatology and the remaining eight were
interviewed by telephone. Interviews were audio recorded and
transcribed verbatim by an independent transcription company.
Member checking was done throughout the interviews.
Data for the Index of Multiple Deprivation (IMD), the official
measure of relative deprivation for small areas in England was
obtained from Ministry of Housing Communities & Local Gov-
ernment, http://imd-by-postcode.opendatacommunities.org. The
IMD ranks every post-code in England from most deprived to
least deprived, and categorises the ranks into deciles. It combines
information from seven domains, namely income deprivation;
employment deprivation; education, skills and training depriva-
tion; health deprivation and disability; crime; barriers to housing
and services; and living environment deprivation to produce an
overall relative measure of deprivation.
2.5. Data analysis
The data were analysed in parallel with the data-collection
process, and initial results informed subsequent sampling and
data collection. Analysis began with open coding to identify con-
cepts and generate codes. Conceptual codes were grouped into
major categories. Analysis proceeded with axial coding exploring
relationships between major categories. The constant comparison
methodwas used, allowing the data to be compared and contrasted
within and between interviews, concepts and major categories
[22]. Memos were also written to capture impressions of the data
and to record emerging concepts and categories. ZL used NVivo
version 11 software [23] to facilitate coding of all transcripts and a
subset was blind-coded by GN. The coders discussed and resolved
any discrepancies – a summary of preliminary findings was also
presented to AA and MD who did not highlight any inconsistencies.
STATA version 14 was used for quantitative data analysis.
3. Results
3.1. Participants
Thirty participants (26 men) were interviewed between April
and July 2017. This was between 18 and 26months after the end
of the RCT: the median post-intervention interval was 22months
(IQR: 19–21months). Participants were aged between 36 and
85years with a mean age of 65.17 (SD 11.51) years and came from
white (n=28), Chinese (n=1) and East-African Asian (n=1) back-
grounds. Theirmedian (IQR) decile for IMD overall was 5 (2–7), and
themedian decile for each domain of IMD is summarized in Table 1.
The mean disease duration was 14.9 (SD 11.12) years. Twenty-
four participants received allopurinol, and the other six received
either fexbuxostat (n=5) or benzbromarone (n=1). Their disease
and demographic characteristicswere similar to the participants in
the main study. SU levels and tophi data before and on completion
of the RCT in these 30 participants are summarised in Table 2. SU
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Table 2
SUA levels and tophi data, before and on completion of the RCT.
SUA (mol/L) (mean± SD) Participants with tophi n (%)
Baseline 439.77±81.06 2 (6.7%)
At 24 months 232.27±44.37 1 (3.3%)
Box 1: Illustrative quotes for themes 1 and 2
Theme 1: Improved understanding of gout and its treatment
..it [long-term ULT use] gets rid of the crystals altogether, which is obviously
the problem lies with the crystals that form.
feel good that I understand what was happening and what caused it [gout]
and why they’ve done it whereas other people I know that are just under the
doctor, they have no real clue,
It’s easy you just take the medication [ULT] and the gout is gone. I can’t be
bothered with my diet.
[After speaking with the nurse] I know things like, for instance, like this thing
called purines, which obviously anything that’s high in purines can cause the
uric acid to build up.
I imagine it [gout] can damage the joints and I imagine [cause] some kind of
kidney disease.
It’s just I don’t know if you’ll ever come off the pills [ULT] (. . .) if your body
produces too much uric acid, you’re stuck with that aren’t you.
Theme 2: Increased confidence
But mostly it’s the talks [with the nurse] that were helpful because dealing
with people who specifically have this condition as an expertise, it’s good to
be able to do that, whilst the GP, he had a knowledge of it but it wasn’t
sufficient to get the situation under control.
Fine, it was absolutely great, she [nurse] explained what would happen, the
targets [optimum uric acid level] that we were aiming to get.
learned the right level of uric acid into the blood, yes, had to be below a
certain limit, always take the pills, don’t forget and I can remember the
side-effects, negative ones.
I took these little tablets [colchicine] in case I got a bout of gout again, to take
those as well [as the ULTs], and [the nurse] explained what they were for and
what these were for and, as I say, I was on [both] tablets when I was on the
study.
levels were not considered in the data analysis process. Analysis of
the participants’ account of their experiences of managing gout led
to the identification of six core themes relating to the role of nurse-
led care in facilitating engagement with ULT. Twenty-nine of the
thirty participants were on ULT at the time of the interview study.
These themes are discussed below and supported with illustrative
quotations in Boxes 1–3.
3.2. Theme 1: improved knowledge and understanding of gout
and its treatment
Participants reported that nurse-led care helped to improve
their understanding of the nature of gout and the role of pharma-
cologic treatment in the long-term management of the condition
(Box 1). Participants while reflecting on their experiences, fre-
quently stated that primary-care practitioners had provided little
information about the role of ULT in the management of gout. Post-
intervention,mostparticipants indicated that increasedknowledge
of the causes and long-term effects of gout fostered their engage-
ment with ULT. Participants accepted that elevated SU levels and
the resulting urate crystal accumulation in the body caused gout.
Most understood that urate crystal accumulation would continue
until the process was treated effectively with ULT. They explained
that they primarily sought to engage with ULT to help lower urate
levels, eliminate the crystals and thus prevent further flares.
While participants understood the role of pharmacologic inter-
ventions in the long-term management of gout, many were
unaware of the importance of simultaneously making lifestyle
adjustments: they preferred to rely on medication alone. However,
many indicated that the provision of dietary information addressed
Box 2: Illustrative quotes for themes 3 and 4
Theme 3: Encouraged persistence
Well the gout study’s a lot more thorough and it’s more individualized – they
adjust the dose and treatment to you, as well, you’re on a personal basis. It’s
hands on and that’s why you engage in it better and get good results.
My flares were coming down, the nurse was doing a wonderful job [up
titrating ULT] but then I went on holiday while I was on the study, forgot to
take my tablets [ULTs] with me, and I had a flare. I thought, ‘I must remember
them.’
The nurse came to do my blood test, she said to me that it [SUA level] was
high. She phoned me straight away, and said, I should increase my dose.
They [nurses] were good, they used to obviously give me a running tally on
my urate level periodically when I used to go in, have a meeting and check
my blood and that. So, it was a lot more in depth and a lot more, you know,
managed.
The doctors, with all due respect to them, I’m a number in a vast amount of
numbers for them. They give you 10 minutes and, you know, I’m not knocking
the doctors at all, but you can’t get the right dose [ULT dose] in 10 minutes.
Theme 4: Involved patients in decision-making about treatment
It’s actually talking and being able to talk to the nurses involved in the study
and getting encouragement from them, the fact that we’re working together,
it’s not just me on my own, seeing the GP.
my brother-in-law had got gout and he was already on the Allopurinol and it
was him that I discussed about, he was saying how good the drug was but
again, he was saying, but once you start on it, you have to continue it. The
nurse said the same.
I was put on it [allopurinol] by the research [intervention] and because it
worked for a bit and then afterwards, it [SUA level] kept going back up again,
it wasn’t working for me, so I discussed it with the nurse, I was put on this
Febuxostat and well, it just brought it [SUA levels] right down.
The first tablet [ULT] they [nurse] put me on, I came out in a rash and so I felt
that it didn’t suit me, she said, ‘It can’t suit you’, and she talked it over with
me and then put me onto the other tablet [ULT].
Box 3: Illustrative quotes for theme 5
Theme 5: Enhanced long-term adherence
And, the medicine [ULT] works for me. I haven’t had a flare since coming out
of the study. I never fail to take it, because I know what will happen to me if I
don’t, I think about it, oh did I take my tablet [ULT], so it’s, religiously I take
that tablet [ULT].
It’s an arthritic condition but I don’t understand, I don’t know if it’s
coincidence, taking the Allopurinol does seem to help with the arthritis so
that would seem to suggest there is some kind of connection somewhere.
misperceptions about the role of diet in the management of gout.
Participantswere alsoworried about the effect of progressive urate
crystal deposition on their joints and the risk of irreversible joint
damage. For most, knowledge of the long-term consequences of
gout togetherwith adesire toprevent furtherflaresbecameadriver
for engagement with treatment.
3.3. Theme 2: increased confidence in ULT
Participants indicated that nurse-led care addressed individual
concerns about using ULT, and this helped them to overcome their
resistance to taking medication (Box 1). Some participants had
previously been prescribed fixed, low-dose ULT by primary-care
practitioners which had failed to prevent flares. These participants
were reluctant to re-engagewithULT until the nurse told them that
thedosageneeded tobeoptimised inorder toprevent furtherflares.
When they discovered that this could be determined bymonitoring
SU levels and up-titrating ULT against a specific target level, below
the saturation point for crystal formation, they were persuaded
to re-engage with ULT. Those with no previous experience of ULT
use also benefitted from information about the up-titrating pro-
cess. In both cases, awareness of the goal of up-titration increased
patients’ confidence in the potential efficacy of ULT, encouraging
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them to begin therapy and engage with the up-titration process.
All participantswere advised that they could experience gout flares
during up-titration and were prescribed pharmacologic treatment
to manage flares. This reassured individuals that the nurse-led
intervention gave equal weight to the management of both acute
and long-term gout.
3.4. Theme 3: encouragement to persist with ULT during the trial
After initiating ULT, participants believed that periodic contact
with the nurse provided them with the impetus to persist with
theirmedication (Box 2).Many participants observed a progressive
reduction in the frequency and severity of flares during the up-
titrationprocess and theyattributed this to receiving individualised
treatment. On observing the results of the new regimen, partici-
pants were determined to continue taking ULT in order to prevent
recurring flares. Some participants did not experience any flares
during the up-titration process and were motivated to continue
with ULT because they understood that gout could flare up again.
Those with previous experience of up-titration under a primary-
care practitioner explained that they had not received information
about the process, found it slow and were demotivated when they
experienced flares as they had expected the treatment to prevent
flares at a much earlier stage.
Participants valued the long-term monitoring and review of
their condition and treatment – frequently suggesting that ongoing
dialogue with a healthcare professional, especially while establish-
ing a new regime, encouraged them to persevere with ULT. Most
suggested that the availability of information on current and target
SU levels provided the psychological motivation to continue with
ULT while determining the optimum dose during an up-titration
process. Participants were impressed by the consistent and timely
access they had to a supportive healthcare professional, and the
speed at which the target SU and optimum ULT dose was achieved.
Both of these meant they suffered minimal inconvenience.
3.5. Theme 4: involved patients in decision-making about
treatment
Individuals indicated that nurse-led intervention involved them
in decision-making about treatment (Box 2). They were able to
explore the risks and benefits of the treatment options available
and make an informed decision about treatment in discussion with
their healthcare professional.Most explained that they shared their
preferences, goals and values, and the healthcare professional com-
municated information about the condition and treatment options.
Some participants had researched treatment options and dietary
restrictions, and bought this knowledge to discussions, as well as
the relevant past experiences of family/friends. Patients with other
medical conditions raised concerns about contraindications of ULT
and interactions with other prescriptions. They were reassured
when nurses provided information about potential side effects and
prescribed the best suited ULT, feeling that their patient-specific
risk factors were being addressed.
3.6. Theme 5: enhanced long-term treatment adherence after end
of trial
Participants explained that engagingwith nurse-led care helped
toprevent furtherflaresof goutwhichmotivated their adherence to
ULT (Box3).Nonehadexperiencedaflare since completing the trial,
and all felt there had been improvements in their physical, psy-
chological and emotional wellbeing as well as their quality of life.
Some also perceived an improvement in overall joint function and
joint-related symptoms, such as the stiffness and pain occasion-
ally associated with other rheumatic conditions. They attributed
Box 4: Illustrative quotes for treatment uncertainty dur-
ing and after the study end
Theme 6: Treatment uncertainty and concern
Allopurinol has quite a lot of side effects and I wonder if I’m on it long term
how that will affect my health and the other medications I’m taking.
Well, I read in, it’s one of the side effects. It [ULT] potentially can raise your
white blood cells, I’m getting no symptoms of gout, I took a chance and
halved it [ULT dose].
I was taking eight paracetamol codeine tablets. I was taking these 14 tablets a
day, that was a lot so I stopped it [ULT]
I’m not sure anybody is monitoring it [uric acid levels] now. Because of my
kidney issues, I get told to have a blood test, if I go to the doctor but I’ve not
had one for gout.
improvements to a treatment approach which prioritised long-
term management of gout rather than focusing just on the flares
in the way primary-care practitioners had often done in their ear-
lier consultations. Individuals feared flares and the prospect of pain
prompted adherence.
3.7. Theme 6: treatment uncertainty and concern
Although most participants reported adhering to ULT, some
raised concerns about long-term use related to prescription costs,
polypharmacy, relative contraindications, overuse, dependency,
long-term impact on health, and side effects (Box 4). Apprehension
about long-term use of medication led to one participant halting
ULT, and another self-adjusting the dose to a lower, personally
acceptable level. Post-intervention, participants were concerned
that there was no long-term monitoring or discussion of ULT
use– although at the end of the study primary-care practitioners
were advised to monitor SU levels annually, very few did.
4. Discussion
This qualitative study explores the role of nurse-led care
designed to improve uptake of ULTs in the control of gout.
Patients found that nurse-led care, unlike general-practitioner care,
improved their knowledge and understanding of gout and the
function of ULTs in its long-term management. Dialogue with a
healthcare professional corrected any misperceptions about gout,
alleviated any concerns about ULT use and allowed patients to
start treatment with increased confidence. Information about up-
titrated ULT and regular monitoring and review of SU levels
reassured patients, encouraging them to persist with ULTs. It is
likely that a reduction in the SU level was perceived as a therapeu-
tic effect of persevering with the medicine, and further promoted
drug adherence in a positive biofeedback loop. Additionally, edu-
cation about the discordance between achieving a therapeutic SU
level relatively early in the course of up-titrated ULT, and, the
continued occurrence of gout flares enabled study participants to
interpret their SU results correctly. This is of major importance in
drug adherence and engagementwithULT. Discussing the risks and
benefits of treatment options allowed patients to make informed
decisions about their healthcare. Adherence to ULTs was promoted
byeffective control of goutwhich improvedqualityof life. Similarly,
acknowledging the side effects of ULT, discussing it, and changing
the treatment when required, would further improve persistence
on treatment. Although a few patients reported an improvement in
non-gout-related joint symptoms, it is not clear from the present
study whether this is attributable to ULTs.
A previous qualitative study exploring factors influencing the
uptake of ULT indicated that patients want to be involved in
decision-making about their treatment, and value a healthcare
approach which involves ‘joint effort over time’ [18]. Our study has
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demonstrated that shared decision-making and such joint efforts
as outlined above persuade patients to initiate ULT, and observing a
reduction in the frequencyof flares encourages themtopersistwith
the therapy. Our findings suggest that knowledge about gout and
understanding of its consequences and treatment enhances patient
receptiveness to ULT and this is supported by other studies which
have noted that increased patient understanding can improvewill-
ingness to take ULTs [18,24–26]. Once ULT has been initiated,
qualitative findings have indicated that patient behaviour and their
perception of the effectiveness of ULT can determine whether they
continue with treatment [18]. In this respect, our findings reveal
that regularmonitoring canmitigate negative behavioural changes.
Findings fromaquestionnaire-based study investigating long-term
adherence to ULT among patients with gout who had received full
information on gout and been monitored by a nurse for one year
suggest that 91% respondents were using ULTs five years after ini-
tiation [19]. This present qualitative exploration shows that when
patients experience the benefits of ULTs, they are motivated to
adhere to long-term gout treatment. Our qualitative study has
shown that nurse led care which provides holistic assessment,
individualised patient education and engagement facilitates ULT
uptake and subsequent persistence.
Participants in this study were interviewed at least 18 months
after their last study visit. Several reported concerns about the lack
of monitoring of SU levels, and absence of any ongoing discussion
with their GP about the need for continuing ULT. This highlights
the importance of regular monitoring of gout, and, suggests that
any long-term package of care for gout should include regular
review (for example, annually) involving discussion about gout sta-
tus,measurement of SU, and assessment of adverse lifestyle factors
and comorbidities.
Using a qualitative approach enabled exploration of how nurse-
led intervention facilitates initiation, persistence, and long-term
adherence to ULT from the perspective of patients. The sample was
designed to include participants who had diverse experiences of
engagement with ULT during the previous RCT, and we included
participants who fit the ‘typical’ gout profile and those who did
not [18]. The most significant limitation of this study is that the
sample consisted of patients who were predominately white and
of an older age and who were all living in the East Midlands. For
cultural and regional reasons, other populations may express dif-
ferent views about the interplay between this type of nurse-led
intervention and engagement with ULT to manage gout. Further-
more, participants in the RCT volunteered to take part and had
experienced at least one flare in the twelve months before com-
mencement of the RCT. It is not clear whether people with less
frequent flares arewilling to engagewithULTs. Finally, participants
were interviewed 18–26 months (median: 22 months) after com-
pleting theRCT. This could influence their ability to accurately recall
experience in the nurse-led care intervention and is a limitation of
the study. Moreover, we did not collect information about educa-
tional attainment, employment status and income level from each
participant in this study. However, their post-code based IMD data
shows that their education, employment and income deprivation
characteristics was below average for the UK, with a median score
of 4th decile. Additionally, we did not measure their SU level at the
time of the interview visit, and are unable to triangulate this with
the results.
5.
In conclusion, we have established from the perspectives of
patients that a nurse-led package of care designed to improve
patient outcomes enables engagementwith ULTs for the long-term
management of gout. However, the findings have also highlighted
that people with gout are concerned about the implications of
long-term medication use and this could prevent adherence. Fur-
thermore, they lack understanding of the complimentary role of
ULT and lifestyle adjustment in controlling gout. Previous qualita-
tive research has suggested that people with gout associate ULTs
with less requirement for dietary restriction and that this percep-
tion encourages ULT use [26]. Further studies are required to:
• develop and test interventions which communicate the risks and
benefits of long-term ULT use in order to address patient-specific
concerns;
• to assessmethodswhich communicatehow lifestyle adjustments
can be used in combination with pharmacologic interventions in
the control of gout.
Such interventions are long overdue in a society with rising
prevalence and incidence of gout but continued suboptimal man-
agement of the condition.
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